Bartlett NL, Sehn LH, Assouline S, Giri P, et al. Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis. Am J Hematol 2026 Mar 20. doi: 10.1002/ajh.70225.
PMID: 41862428